Browse the evidence

In older adults, the muscle protein synthesis response to protein ingestion is blunted (anabolic resistance), and simply increasing protein intake does not overcome this resistance.

As you age, your muscles become less responsive to protein. Simply eating more protein won't build muscle. You must combine adequate protein intake with resistance exercise to overcome this 'anabolic resistance' and stimulate muscle growth.

Accelerometer-derived summary metrics (MIMS-unit, AAI, MAD, ENMO) derived from raw data provide greater comparability across different device manufacturers and models than traditional proprietary activity counts.

If you are a researcher, stop relying on proprietary 'counts' to compare studies. Use open-source raw data algorithms (like MIMS-unit or AAI) to ensure your findings are comparable across different device brands. If you are a consumer, understand that 'steps' or 'activity scores' from different brands are not mathematically equivalent, even if they look similar.

Food industry donations to academic programs create conflicts of interest by influencing research design, minimizing criticism of harmful products, and shaping public policy, often without transparent disclosure of the donation's purpose.

When evaluating health or nutrition research funded by food companies, check for disclosed conflicts of interest. If a study is funded by an industry with a vested interest in the outcome (e.g., sugary drinks funding obesity research), scrutinize the study design and conclusions more heavily, as industry funding is correlated with outcomes favorable to the sponsor.

Equating total load lifted (volume) during acute resistance training renders exercise intensity (35% vs 70% 1RM) irrelevant for acute neurotrophic factor (BDNF, NGF) responses.

If you want to stimulate brain-derived neurotrophic factors (BDNF) through resistance training, you do not need to lift heavy weights. As long as you lift the same total amount of weight (volume) as someone lifting heavy, your brain gets the same acute signal. This allows for joint-friendly training using lighter loads (e.g., 35% 1RM) to achieve similar neurotrophic outcomes to heavier loads (70% 1RM).

Deregulation of dietary supplement health claims, driven by political lobbying rather than scientific evidence, has led to a proliferation of unproven therapeutic claims and increased industry revenue without corresponding public health benefits.

Be skeptical of health claims on supplement labels that do not explicitly state 'This statement has not been evaluated by the Food and Drug Administration.' If a product claims to 'support' a bodily function (e.g., immune, joint, cardiovascular) without citing specific, significant scientific agreement, it likely lacks robust clinical evidence. Prioritize products with transparent sourcing and third-party testing, and consult a healthcare provider before using supplements to treat or prevent diseases, as the regulatory environment allows for marketing claims that may not reflect scientific reality.

Prolonged use of Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for 3 years or more can enhance beta-cell function.

For those who cannot or will not undergo surgery or strict dieting, long-term GLP-1 agonist therapy (3+ years) may help preserve your pancreas's insulin-producing capacity. This is a disease-modifying effect, not just glucose lowering.

Cardiac diastolic function, specifically the E/e' ratio and Left Atrial Volume Index (LAVI), significantly moderates the reduction in relative peak oxygen uptake in Type 2 Diabetes patients.

For T2D patients, standard cardiac checks might miss the root cause of exercise intolerance. If you struggle with exercise despite normal ejection fraction, ask about diastolic function (E/e' ratio). Addressing this through specific training (like high-intensity interval training, as suggested by the authors) may be more effective than generic advice.

Enhanced care interventions (physician letter, personalized chart, and registered dietitian counseling) do not significantly improve gestational weight gain outcomes compared to usual care in the aggregate population of women with pregestational obesity.

For pregnant women with obesity, adding intensive lifestyle interventions (dietitian visits, personalized charts, physician letters) to standard care does not significantly improve overall gestational weight gain outcomes compared to standard care alone. However, this lack of benefit is driven by Class I and II obesity patients who do well with standard care; Class III obesity patients specifically benefit from the enhanced intervention.

Women with Class I or Class II obesity achieve better gestational weight gain outcomes with usual care compared to enhanced care interventions.

For pregnant women with Class I or II obesity, standard obstetric care and written educational materials are sufficient to achieve healthy weight gain. Adding intensive lifestyle interventions (dietitian visits, personalized charts) does not improve outcomes and may be unnecessary resource expenditure for these patients.

GLP-1 receptor agonists increase perioperative aspiration risk due to delayed gastric emptying, requiring specific holding protocols before elective surgery.

If you are having elective surgery while taking GLP-1 medications, tell your surgeon and anesthesiologist. You may need to hold your medication before surgery to reduce the risk of aspiration. Follow the specific holding instructions provided by your medical team.

SGLT2 inhibitors reduce blood pressure and cardiovascular risk, potentially through central sympatho-inhibition, but do not necessarily reduce muscle sympathetic nerve activity (MSNA) in humans.

SGLT2 inhibitors (like Jardiance or Farxiga) lower blood sugar and protect the heart. While they work by removing glucose through urine, they may also have subtle effects on brain pathways that help lower blood pressure.

Tirzepatide (a dual GIP/GLP-1 receptor agonist) significantly improves hepatic steatosis and increases the likelihood of MASH resolution without worsening fibrosis in patients with non-cirrhotic MASH.

If you have MASH without cirrhosis, ask your doctor about tirzepatide. Clinical trials show that weekly injections of 5-15mg can significantly resolve MASH and improve liver fat without worsening fibrosis. This is a promising option for managing liver health in addition to blood sugar and weight.

Resmetirom is approved for adults with non-cirrhotic MASH and advanced liver fibrosis (stage ≥ 2) and has shown histological efficacy in addressing steatohepatitis and fibrosis.

If you have MASH with advanced fibrosis but no cirrhosis, ask your doctor about resmetirom. It is an approved treatment that has been shown to improve both steatohepatitis and fibrosis with a favorable safety profile.

Bariatric surgery significantly reduces the risk of developing heart failure and improves mortality in patients with existing heart failure and obesity.

For severe obesity, bariatric surgery is a highly effective treatment that can prevent heart failure and significantly improve survival in those who already have it. It is safe and can even be used as a bridge to heart transplantation in severe cases. Consult with a bariatric surgeon and cardiologist to see if you are a candidate.

GLP-1 RAs improve histological markers of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and reduce liver fat in patients with MASLD, MetALD, and ALD.

If you have fatty liver disease (MASLD/MASH), GLP-1 medications like Semaglutide or Liraglutide can significantly improve liver inflammation and fat content, often leading to MASH resolution. This is especially beneficial if you also have obesity or Type 2 Diabetes. Discuss these options with your hepatologist, noting that while they improve liver histology, they may not always reverse advanced fibrosis.

GLP-1 receptor agonist therapy causes a significant increase in resting heart rate (RHR) during the initial 12 weeks of treatment, which is primarily mediated by a reduction in heart rate variability (HRV).

If you start a GLP-1 medication (like semaglutide or tirzepatide), expect your resting heart rate to increase by about 3 beats per minute over the first 3 months. This is a normal, mediated response involving your autonomic nervous system (HRV), not necessarily a sign of heart damage. If you use a wearable, track this trend, but consult your doctor if the increase is extreme or accompanied by other symptoms.

Bariatric surgery prevents the onset of type 2 diabetes in obese patients without preexisting diabetes, with incidence rates significantly lower than non-surgical obese controls.

If you are obese but do not yet have diabetes, bariatric surgery can significantly reduce your risk of developing it over the next 15 years compared to lifestyle changes alone. While surgery is invasive, the long-term data shows it is a highly effective preventive strategy for those with severe obesity.

SGLT2 inhibitors improve vascular function by reducing arterial stiffness, improving endothelial function (flow-mediated dilation), and reducing inflammation and oxidative stress.

These drugs don't just lower sugar; they physically improve the health of your blood vessels by making them more flexible and reducing the chemical stress (inflammation/oxidative stress) that damages them over time.

Bariatric surgery, specifically Roux-en-Y gastric bypass (RYGB), is a highly effective treatment for severe obesity, providing rapid and durable weight loss, though it carries risks of adverse events and nutritional deficiencies.

For individuals with severe obesity (BMI >40 or >35 with comorbidities), bariatric surgery like RYGB is a highly effective, durable treatment. It is not a cosmetic procedure but a medical intervention for severe disease. Patients must be prepared for lifelong nutritional monitoring to prevent deficiencies.

Obese individuals attempting self-directed weight loss do not increase energy expenditure or physical activity patterns (NEAT, EAT, steps) to achieve weight loss; weight loss is driven by reduced energy intake (modified nutritional habits) rather than increased energy expenditure.

If you are trying to lose weight on your own, do not rely on increasing your physical activity or exercise to drive the weight loss. This study shows that people who successfully lose weight do not increase their energy expenditure, steps, or exercise time compared to those who don't. Instead, focus on modifying your nutritional habits, specifically by reducing the frequency of unfavorable foods (high fat, high glycemic index) and increasing favorable foods. Weight loss is achieved through dietary changes, not by moving more.

The reduction in schizophrenia risk associated with GLP-1 receptor agonists is mediated by body mass index (BMI) rather than glycemic control.

The mental health benefits of GLP-1 drugs for schizophrenia risk appear to come from weight loss, not from lowering blood sugar. This means that interventions focusing on weight management (whether through GLP-1 drugs or other means) may be the key to reducing this specific psychiatric risk. It highlights the importance of addressing obesity in mental health prevention strategies.

Peripheral GLP-1 receptor agonists (GLP-1RAs) exert brain-mediated anorectic effects primarily via access to circumventricular organs (CVOs) like the area postrema and median eminence, rather than crossing the blood-brain barrier (BBB) or blood-cerebrospinal fluid barrier (BCB).

GLP-1 medications like Semaglutide and Liraglutide reduce appetite by signaling from the gut to specific brain regions (CVOs) via the vagus nerve, rather than crossing into the brain tissue itself. This explains why they are effective for weight loss even though very little drug actually enters the cerebrospinal fluid.

Body weight stigma acts as a significant barrier to healthcare engagement and long-term weight management success.

If you feel judged by healthcare providers, it is a common and valid experience that can hinder your care. Seek out providers who practice weight-inclusive or stigma-informed care. Addressing the psychological burden of stigma is a crucial part of effective obesity management.

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) cause dose-dependent gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) primarily during dose escalation, leading to discontinuation in 3-17% of non-diabetic users.

If you are using a GLP-1 medication like semaglutide or tirzepatide, expect gastrointestinal side effects like nausea and diarrhea, especially when starting or increasing the dose. These symptoms are common but usually mild and transient. To manage them, follow a slow titration schedule, eat smaller, low-fat meals, and stay hydrated. Most people adapt over time, but if side effects are severe, consult your doctor about adjusting the dose.